Survodutide shows weight loss and glycemic gains in phase 2 trial
Boehringer Ingelheim's glucagon/GLP-1 dual agonist adds mid-stage data as the incretin field broadens beyond GIP-based combinations.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 7 05:56 ETSource: PharmaTimes
The wire
- 01PharmaTimes reports phase 2 results for survodutide showing both weight reduction and improved glycemic control.
- 02Survodutide's glucagon receptor component gives prescribers a different mechanism to track against tirzepatide and retatrutide as later-stage data accumulate.
- 03Phase 2 findings are not confirmatory; tolerability, dose titration and durability remain to be established in larger phase 3 work.
From the source
Read at pharmatimes.comSurvodutide delivers weight loss and glycemic gains in phase 2 trial
